Does Affinity Health Plan Cover Lantus?

Affinity Health Plan No Longer Exists as a Separate Insurer

Affinity Health Plan was a nonprofit Medicaid managed care organization based in the Bronx, New York, serving approximately 250,000 members across New York City and surrounding counties. In 2014, Molina Healthcare acquired Affinity Health Plan, and all Affinity members transitioned to Molina Healthcare of New York plans. If you are searching for Affinity Health Plan's drug formulary, you need to check Molina's current formulary instead.

What Happened to Affinity Members

All former Affinity Health Plan enrollees were automatically transitioned to equivalent Molina Healthcare Medicaid managed care plans. Benefit structures, provider networks, and formulary drug lists changed to align with Molina's contracts with New York State. Your prescription drug coverage, including insulin, is now governed entirely by Molina Healthcare's policies and the New York State Medicaid Drug Utilization Review Board's preferred drug list.

How to Verify Your Current Coverage

Call the phone number on the back of your Molina member ID card or log in to the Molina Healthcare member portal. The New York State Medicaid preferred drug list (PDL) is publicly available through the New York Department of Health and is updated quarterly. Any insulin glargine product on the state PDL must be covered by all Medicaid managed care plans operating in New York, including Molina.

How Medicaid Managed Care Plans in New York Cover Lantus

New York Medicaid requires all managed care organizations to cover medications on the state's preferred drug list. Insulin products receive broad Medicaid coverage because untreated or undertreated diabetes carries enormous downstream costs. The American Diabetes Association estimates that diagnosed diabetes costs the U.S. Healthcare system $412.9 billion annually, with inpatient care and insulin therapy among the largest cost drivers.

Preferred vs. Non-Preferred Insulin Glargine Products

Most New York Medicaid managed care plans designate one or more insulin glargine products as "preferred." Brand-name Lantus (manufactured by Sanofi) competes with several biosimilar and follow-on products:

| Product | Manufacturer | FDA Status | Typical Medicaid Tier | |---|---|---|---| | Lantus (insulin glargine) | Sanofi | Original biologic | Preferred or non-preferred (varies by plan year) | | Basaglar (insulin glargine) | Eli Lilly | Follow-on biologic | Often preferred | | Semglee (insulin glargine-yfgn) | Biocon/Viatris | Interchangeable biosimilar | Often preferred | | Rezvoglar (insulin glargine-aglr) | Eli Lilly | Biosimilar | Varies |

When a biosimilar is listed as preferred, brand Lantus may require prior authorization or a step-through requirement. This means your prescriber must document that you tried the preferred product first, or provide clinical justification for why brand Lantus is medically necessary.

Copay Expectations Under New York Medicaid

New York Medicaid enrollees pay $0 to $3 for most covered prescriptions. Insulin is classified as a medically necessary drug, and cost-sharing for Medicaid beneficiaries is federally capped at nominal amounts. If you are enrolled in a Molina Medicaid managed care plan and your insulin glargine product is on the formulary, your out-of-pocket cost will be minimal.

Lantus (Insulin Glargine): Clinical Profile

Insulin glargine is a long-acting basal insulin analog first approved by the FDA in 2000. It provides approximately 24 hours of blood glucose control with a relatively flat pharmacokinetic profile compared to older NPH insulin formulations [1].

Mechanism and Dosing

Lantus works by forming microprecipitates after subcutaneous injection, which slowly dissolve and release insulin glargine into the bloodstream. Standard starting doses for adults with type 2 diabetes range from 10 units once daily to 0.2 units/kg/day, titrated based on fasting blood glucose targets. The ORIGIN trial (N=12,537) demonstrated that early initiation of insulin glargine in patients with cardiovascular risk factors and dysglycemia maintained HbA1c at 6.2% over a median 6.2 years without increasing cardiovascular events [2].

Efficacy Data

The EDITION clinical trial program compared Lantus to its concentrated formulation (Toujeo, insulin glargine 300 units/mL) across multiple populations. In EDITION 1 (N=807), patients with type 2 diabetes on basal-bolus therapy achieved comparable HbA1c reductions with both formulations, but the 300 units/mL version showed fewer confirmed nocturnal hypoglycemic events (risk ratio 0.78, P=0.004) [3]. For most Medicaid formulary purposes, standard Lantus (100 units/mL) and its biosimilars remain the default covered products.

Safety Considerations

Common side effects include injection-site reactions, hypoglycemia, and weight gain. In the ORIGIN trial, insulin glargine was associated with a modest mean weight gain of 1.6 kg over 6.2 years compared to standard care [2]. Severe hypoglycemia occurred in approximately 1.0 event per 100 patient-years. Patients switching between insulin glargine products should monitor blood glucose closely during the first weeks, though the FDA's interchangeability designation for Semglee confirms that pharmacy-level substitution is appropriate without prescriber intervention [4].

Cost of Lantus Without Insurance and Savings Options

Brand Lantus carries a wholesale acquisition cost (WAC) exceeding $350 per box of five 3 mL pens. For patients without adequate insurance coverage, this price creates a significant barrier. The CDC reports that approximately 1 in 4 insulin users in the United States have rationed insulin due to cost, a practice associated with diabetic ketoacidosis, hospitalization, and death [5].

The $35 Insulin Cap Under the Inflation Reduction Act

The Inflation Reduction Act of 2022 capped out-of-pocket insulin costs at $35 per month for Medicare Part D enrollees starting January 2023. This cap applies to all Medicare-covered insulin products, including Lantus and its biosimilars. New York Medicaid enrollees already had nominal copays, so the practical impact in this population was smaller. However, patients transitioning from Medicaid to Medicare (for example, dual-eligible individuals aging into Medicare) benefit substantially from this federal cap [6].

Sanofi Patient Assistance Programs

Sanofi offers the Insulins Valyou Savings Program, which caps Lantus costs at $35 per month for patients who are uninsured or whose insurance does not cover the product. Separately, the Sanofi Patient Connection program provides free Lantus to patients who meet income eligibility criteria (generally at or below 400% of the federal poverty level). These programs require annual re-enrollment and are not available to patients enrolled in government-funded insurance programs like Medicaid or Medicare.

Biosimilar Price Advantages

Biosimilar insulin glargine products offer meaningful savings at the pharmacy counter. Semglee, the first interchangeable insulin biosimilar approved in the United States, launched at a list price approximately 65% lower than brand Lantus. For Medicaid managed care organizations, selecting a biosimilar as the preferred formulary product reduces per-member-per-month pharmacy spend, which is one reason plans frequently prefer Semglee or Basaglar over brand Lantus.

How to Get Lantus Covered If Your Plan Prefers a Biosimilar

If your Molina Healthcare plan (or any other New York Medicaid managed care plan) lists a biosimilar as preferred and you need brand Lantus specifically, your prescriber can submit a prior authorization request. The American Diabetes Association's Standards of Care in Diabetes note that insulin formulation preferences should account for individual patient factors including injection device familiarity, dosing precision, and prior adverse reactions [7].

Step Therapy and Exception Requests

Step therapy (also called "fail first") requires documentation that you tried the preferred product and experienced an inadequate response or adverse effect. Common acceptable reasons for a brand Lantus exception include:

• Documented allergic reaction to an excipient in the biosimilar product
• Demonstrated glycemic instability after switching from brand to biosimilar
• Patient inability to use the biosimilar's delivery device (pen or vial differences)
• Prescriber's clinical judgment supported by blood glucose logs or continuous glucose monitoring data

Timeline for Prior Authorization Decisions

New York Medicaid regulations require managed care plans to issue standard prior authorization decisions within 24 hours for prescription drugs. Urgent requests must be processed within the same timeframe. If your prior authorization is denied, you have the right to an expedited fair hearing through the New York State Office of Temporary and Disability Assistance.

Comparing Insulin Glargine Products for Medicaid Enrollees

All insulin glargine products on the U.S. Market deliver the same active molecule at the same concentration (100 units/mL for standard formulations). The FDA's biosimilar approval pathway requires demonstration of no clinically meaningful differences in safety, purity, or potency compared to the reference product [4].

Clinical Equivalence Data

The INSTRIDE trials evaluated Semglee against Lantus in patients with type 1 and type 2 diabetes. INSTRIDE 1 (N=558) found that the mean difference in HbA1c change from baseline was 0.05%, well within the prespecified equivalence margin of ±0.4% [8]. INSTRIDE 2 (type 2 diabetes, N=560) confirmed similar findings with comparable hypoglycemia rates between groups.

Device and Packaging Differences

While the insulin molecule is identical, pen devices differ between manufacturers. Lantus SoloStar, Basaglar KwikPen, and Semglee pens each have distinct injection mechanisms, dose dials, and needle compatibility. Patients accustomed to one device may need brief education when switching. The ADA recommends that healthcare providers ensure adequate device training whenever an insulin product change occurs [7].

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "No patient should face barriers to affordable insulin. The availability of biosimilar and interchangeable insulin products is a positive step, but coverage policies must ensure that patients can access the specific product that works best for them."

New York State Medicaid Insulin Coverage Field

New York has been among the more progressive states in Medicaid insulin coverage. Governor Kathy Hochul signed legislation in 2024 requiring all state-regulated health plans to cap insulin copays at $35 per 30-day supply, extending protections beyond the federal Medicare cap to commercial and Medicaid managed care enrollees.

Formulary Update Cycles

The New York State Medicaid Drug Utilization Review Board reviews and updates the preferred drug list on a quarterly basis. Insulin products are evaluated based on clinical evidence, cost-effectiveness, and rebate agreements with manufacturers. Formulary changes take effect at the start of each quarter, and managed care plans must implement updates within 30 days of notification.

Continuous Glucose Monitoring Coverage

New York Medicaid also covers continuous glucose monitors (CGMs) for patients on insulin therapy who meet clinical criteria. The DIAMOND trial (N=158) demonstrated that CGM use in patients on multiple daily insulin injections reduced HbA1c by 0.6% more than self-monitoring of blood glucose alone over 24 weeks [9]. Access to CGM technology can improve insulin dosing accuracy and reduce hypoglycemia risk regardless of which insulin glargine product you use.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, noted in a 2023 review: "The therapeutic equivalence of insulin glargine biosimilars is well-established. The real barrier for most patients is not which glargine product they use, but whether they can afford and consistently access any insulin at all."

What to Do If You Were on Affinity Health Plan

If you were previously an Affinity Health Plan member and are now enrolled in Molina Healthcare of New York, follow these steps to confirm your Lantus coverage:

1. Locate your current Molina member ID card and note your plan type (Medicaid, Medicare-Medicaid, or marketplace)
2. Search the Molina Healthcare drug formulary online or call member services at the number on your card
3. Ask specifically whether insulin glargine (brand Lantus or biosimilar) is on your plan's preferred drug list
4. If brand Lantus requires prior authorization, ask your prescriber to submit the request with supporting clinical documentation
5. If you are denied coverage, request an internal appeal through Molina and, if necessary, a fair hearing through New York State

For patients who have lost Medicaid coverage due to the post-pandemic eligibility redetermination process, the Sanofi Insulins Valyou Savings Program and Lilly Insulin Value Program both offer capped pricing while you reapply or transition to other coverage.